Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)
✍ Scribed by Francesca Fioredda; Michaela Calvillo; Sonia Bonanomi; Tiziana Coliva; Fabio Tucci; Piero Farruggia; Marta Pillon; Baldassarre Martire; Roberta Ghilardi; Ugo Ramenghi; Daniela Renga; Giuseppe Menna; Anna Pusiol; Angelica Barone; Eleonora Gambineri; Giovanni Palazzi; Gabriella Casazza; Marina Lanciotti; Carlo Dufour
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 144 KB
- Volume
- 87
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
The management of congenital and acquired neutropenias presents some differences according to the type of the disease. Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is not standardized and scanty data are available on the best schedule to apply. The frequency and the type of longitudinal controls in patients affected with neutropenias are not usually discussed in the literature. The Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document that includes recommendations on neutropenia treatment and timing of follow-up.